Search

Your search keyword '"Żorniak M"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Żorniak M" Remove constraint Author: "Żorniak M"
30 results on '"Żorniak M"'

Search Results

6. Quality of Life and Clinical Outcomes of Endosonography-Guided Biliary Drainage in Patients with Malignant Biliary Obstruction: A Single-Center, Prospective Analysis.

7. Multimodal treatment with endoscopic ablation and systemic therapy for cholangiocarcinoma.

8. Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis.

9. Machine learning-based decision tool for selecting patients with idiopathic acute pancreatitis for endosonography to exclude a biliary aetiology.

10. Liver phenotypes in PCOS: Analysis of exogenous and inherited risk factors for liver injury in two European cohorts.

12. Clinical Usefulness of Non-Invasive Metabolic-Associated Fatty Liver Disease Risk Assessment Methods in Patients with Full-Blown Polycystic Ovary Syndrome in Relation to the MRI Examination with the Ideal IQ Sequence.

13. Impact of tumor size and location on endoscopic ultrasound-guided sampling of pancreatic neuroendocrine tumors: A recursive partitioning analysis.

14. Practical approach to linear EUS examination of the mediastinum.

16. COVID-19 and Canadian Gastroenterology Trainees.

17. Impact of COVID-19 on endoscopy trainees: an international survey.

18. What Do We Currently Know about the Pathophysiology of Alcoholic Pancreatitis: A Brief Review.

21. Risk Stratification and Early Conservative Treatment of Acute Pancreatitis.

22. Mucosal miR-3677 is over-expressed in cirrhotic patients with gastric antral vascular ectasia (GAVE).

23. Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis.

24. New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.

25. Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease.

26. Portal vein thrombosis in cirrhosis is not associated with intestinal barrier disruption or increased platelet aggregability.

27. From the stomach to other organs: Helicobacter pylori and the liver.

28. Motility disorders, functional gastrointestinal disorders, inflammatory bowel disease and cardiac rhythm disturbances - is there a link? Review of literature.

29. Visfatin and TGF-Β1 in primary biliary cirrhosis and two other common liver diseases.

30. [Derivatives of 1,4-dihydropyridines as "priviledged structures" and their pharmacological potential].

Catalog

Books, media, physical & digital resources